Revenue: US$28.8b (up 6.0% from FY 2023). Net income: US$480.0m (down 92% from FY 2023). Profit margin: 1.7% (down from 21% in FY 2023). EPS: US$0.39 (down from US$4.54 in FY 2023). Revenue ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

According to the Hebron Fire Department, at around 4:48 p.m. firefighters and troopers were deployed to the scene of Gilead Street for reports of a two-car accident involving a rollover.

(RTTNews) - Gilead Sciences (GILD) announced that the FDA has accepted its New Drug Application submissions for lenacapavir-the twice-yearly injectable HIV-1 capsid inhibitor-for the prevention of ...

With the FDA approval of Gilead's seladelpar, there have now been two in a matter of weeks. The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Is Google Maps not working? The app is fairly reliable, but it’s not impossible to run into an issue on occasion. Of course, it’s never fun when technology isn’t performing as intended ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

– Gilead Also Recently Submitted Applications for Lenacapavir for PrEP to the European Medicines Agency That Will Be Reviewed Under Accelerated Assessment Review Timeline – FOSTER CITY, ...